CClinicalTrials.gg
Sign In
RecruitingNCT06207032Updated Feb 24, 2026

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

An observational study in Cancer, sponsored by Tempus AI. Recruiting at 32 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Tempus AI · Observational

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years to 99 Years
Sex
All
01

Study summary

This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • ctDNA
  • Next-Generation Sequencing
  • Oncology
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,486 are open to participants now.

This study's planned enrollment of 500 is above the median of 205 across 1,680 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Tempus AI is the lead sponsor of 14 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants diagnosed with cancer willing to have additional blood samples collected for ctDNA research.

Inclusion criteria

  1. ≥18 years of age
  2. Willing to participate in the research
  3. Able to provide informed consent
  4. Must be diagnosed with cancer

Exclusion criteria

Exclusion Criteria:

1. Not willing or able to have additional blood samples collected

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 001: KRAS mutated CRC

    No intervention.

  • Cohort 002: KRAS mutated PDAC

    No intervention.

  • Cohort 003: KRAS mutated NSCLC

    No intervention.

  • Cohort 004: Gastric 1L Plus

    No intervention.

  • Cohort 005: mCRPC 1L Plus

    No intervention.

  • Cohort 006: Pan Tumor ADCs

    No intervention.

  • Cohort 007: Stage III-IV EGFR Activating Mutation NSCLC

    No intervention.

06

What researchers measure

Primary outcomes

  1. Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.

    Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.

    Time frame: 5 years

Secondary outcomes

  1. Generation of DNA, RNA, immune and other multiomic datasets.

    Use blood and tissue based next generation sequencing to uncover biomarkers that may predict outcomes, identify markers related to disease, identify markers related to mechanism of drug action, and inform future research.

    Time frame: 5 years

07

Study locations

25 of 32 sites recruiting
  • Alabama Oncology
    Birmingham, Alabama 35233, United States
    Recruiting
  • PIH Health Whittier Hospital & PIH Health Physicians
    Whittier, California 90605, United States
    Recruiting
  • Eastern CT and Hematology and Oncology Associates
    Norwich, Connecticut 06360, United States
    • James Champlin · Contact · jchamplin@echoct.com · 860-886-8362
    • Dennis Slater · Principal investigator
    Recruiting
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
    Recruiting
  • Morehouse
    Atlanta, Georgia 30310, United States
    Recruiting
  • Piedmont Healthcare
    Atlanta, Georgia 30318, United States
    Recruiting
  • Southern Illinois Healthcare
    Carterville, Illinois 62918, United States
    Recruiting
  • Hope and Healing Cancer Services
    Hinsdale, Illinois 60521, United States
    Recruiting
  • Cancer Care Specialists of Illinois
    O'Fallon, Illinois 62269, United States
    Recruiting
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
    Recruiting
  • Northwest Oncology and Hematology
    Rolling Meadows, Illinois 60008, United States
    Terminated
  • Fort Wayne
    Fort Wayne, Indiana 46804, United States
    Terminated
  • Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
    Recruiting
  • St. Claire Healthcare
    Morehead, Kentucky 40351, United States
    Terminated
  • Frederick Health Regional System
    Frederick, Maryland 21702, United States
    Recruiting
  • Southcoast Centers for Cancer Care
    Fairhaven, Massachusetts 02719, United States
    Recruiting
  • Hannibal Regional Healthcare System, Inc.
    Hannibal, Missouri 63401, United States
    Recruiting
  • Lake Regional Health
    Osage Beach, Missouri 65065, United States
    Recruiting
  • Mosaic Life Care
    Saint Joseph, Missouri 64506, United States
    Active, not recruiting
  • Oncology Hematology Associates
    Springfield, Missouri 65807, United States
    Recruiting
  • Hope Cancer Care of Nevada
    Las Vegas, Nevada 89103, United States
    Terminated
  • Cancer Care Specialists - Reno
    Reno, Nevada 89511, United States
    • Layla Tapia · Contact · ltapia@ccsreno.com · 775-329-0222
    • Aaron Bowman, MD · Principal investigator
    Recruiting
  • New Jersey Cancer Center
    Belleville, New Jersey 07109, United States
    Terminated
  • Regional Cancer Care Associates
    Belleville, New Jersey 07109, United States
    Terminated
  • Hematology Oncology Associates of Central NY
    East Syracuse, New York 13057, United States
    Recruiting
  • Cayuga Medical Center
    Ithaca, New York 14850, United States
    • Danielle Rao · Contact · drao@cayugamed.org · 607-252-3939
    • Nisha Ajit · Principal investigator
    Recruiting
  • Sanford Roger Maris Cancer Center (Fargo)
    Fargo, North Dakota 58102, United States
    Recruiting
  • Aultman Medical Group
    Canton, Ohio 44710, United States
    Recruiting
  • Taylor Cancer Research Center
    Maumee, Ohio 43537, United States
    Recruiting
  • Cancer Care Associates of York
    York, Pennsylvania 17403, United States
    Recruiting
  • Cancer Care Northwest
    Spokane, Washington 99216, United States
    Recruiting
  • Pan American Center for Oncology Trials
    Rio Piedras, Puerto Rico 00935, Puerto Rico
    Recruiting
08

References and documents

Publications

  • Thomas M. Pharma and the benefits of Real World Data. Drug Discovery World (DDW). Published November 4, 2021. Accessed May 5, 2023. https://www.ddw-online.com/trends-analysis-pharma-and-the-benefits-of-real-world-data-13702-202111/
  • Office of the Commissioner. Oncology Real World Evidence Program. U.S. Food and Drug Administration. Accessed May 5, 2023. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-real-world-evidence-program
  • Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3. PubMed 29968853 ↗
  • Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023 Feb;11(2):e005344. doi: 10.1136/jitc-2022-005344. PubMed 36796877 ↗
  • Grayson N. Real-world data can help make better drugs and do it faster. STAT. Published May 2, 2018. Accessed May 5, 2023. https://www.statnews.com/2018/05/02/real-world-data-drug-development/
  • Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; Draft guidance for industry. Accessed September 8, 2023. https://www.fda.gov/media/158072/
  • Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, Sorrells S, Baker T, Chang A, Michuda J, Iguartua C, MacNeil S, Shah K, Ellis P, Yeatts K, Mahon B, Taxter T, Bontrager M, Khan A, Huether R, Lefkofsky E, White KP. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019 Mar 22;10(24):2384-2396. doi: 10.18632/oncotarget.26797. eCollection 2019 Mar 22. PubMed 31040929 ↗
  • Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019 Nov;37(11):1351-1360. doi: 10.1038/s41587-019-0259-z. Epub 2019 Sep 30. PubMed 31570899 ↗
  • Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac'hmeur A, McKinnon KE, Perera J, Zhu W, Dowlati A, White KP, Tell R, Beaubier N. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021 Jul 2;5(1):63. doi: 10.1038/s41698-021-00202-2. PubMed 34215841 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06207032
Lead sponsor
Tempus AI
Responsible party
Sponsor
First posted
Jan 16, 2024
Start date
Jun 26, 2024
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Feb 24, 2026

Study contacts

Lauren Lopez
Contact
aries@tempus.com
8007394137
Michelle Ting-Lin, MD
study director · Tempus AI, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

Tempus AI

Start the discussion